Literature DB >> 25382108

Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era.

Adam M Petrich1, Irene B Helenowski, Locke J Bryan, Shaina A Rozell, Robert Galamaga, Chadi Nabhan.   

Abstract

Current prognostic models for peripheral T-cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current patients. We utilized the Surveillance Epidemiology and End Results (SEER)-18 database to evaluate factors affecting overall survival (OS) of PTCL in the modern era and identified 8802 patients between 2000-2010. Most subtypes of PTCL increased in incidence during the study period. In univariate analyses, age >55 years, black race, advanced stage, absence of extra-nodal disease, omission of radiation therapy (RT) and high-risk histology each predicted inferior OS (P < 0·0001). Multivariate analysis (MVA) demonstrated that hepatosplenic, enteropathy-associated and extra-nodal Natural Killer/T cell histologies, each had hazard ratios >1·5 (P ≤ 0·0001) for death. Further, age ≥55 years, black race and advanced stage maintained their significance in the MVA (P < 0·0001 each). Based on the significant factors, a prognostic model was constructed and subsequently validated in an independent cohort. The new model incorporated age, stage, histology and race, with an OS ranging from 9 months (highest risk group) to 120 months (lowest risk group). In summary, this is the largest study of PTCL patients in the modern era that provides risk stratification utilizing a new prognostic model that can be incorporated into future prospective clinical trials.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  T-cell lymphoma; histopathology; prognostic factors; radiotherapy

Mesh:

Year:  2014        PMID: 25382108     DOI: 10.1111/bjh.13202

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

2.  Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.

Authors:  Adam J Olszewski; Thomas Ollila; John L Reagan
Journal:  Br J Haematol       Date:  2018-04-24       Impact factor: 6.998

3.  Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Authors:  Gerald G Wulf; Bettina Altmann; Marita Ziepert; Francesco D'Amore; Gerhard Held; Richard Greil; Olivier Tournilhac; Thomas Relander; Andreas Viardot; Martin Wilhelm; Christian Wilhelm; Antonio Pezzutto; Josee M Zijlstra; Eric Van Den Neste; Pieternella J Lugtenburg; Jeanette K Doorduijn; Michel van Gelder; Gustaaf W van Imhoff; Florian Zettl; Friederike Braulke; Maike Nickelsen; Bertram Glass; Andreas Rosenwald; Philippe Gaulard; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper
Journal:  Leukemia       Date:  2020-05-07       Impact factor: 11.528

4.  Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.

Authors:  Scott V Adams; Polly A Newcomb; Andrei R Shustov
Journal:  J Clin Oncol       Date:  2016-03-20       Impact factor: 44.544

5.  Peripheral T-cell lymphoma, not otherwise specified- Case report.

Authors:  Nariman Khan; Collin Clay; Andrew Donati
Journal:  Ann Med Surg (Lond)       Date:  2020-05-30

6.  Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.

Authors:  Luís Alberto de Pádua Covas Lage; Débora Levy; Flávia Dias Xavier; Diego Cândido Reis; Renata de Oliveira Costa; Marianne Castro Gonçalves; Vanderson Rocha; Maria Cláudia Nogueira Zerbini; Juliana Pereira
Journal:  Oncotarget       Date:  2019-08-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.